NCT07247227

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

Sugemalimab Plus Platinum-based Chemotherapy as First-line Therapy for Patients With Locally Advanced and Metastatic Non-small Cell Lung Cancer (NSCLC) in a Real-world Setting: a Single-arm, Multi-center Study

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Peking Union Medical College · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This single-arm, multi-center study is to evaluate Sugemalimab plus platinum-based chemotherapy as first-line therapy for patients with locally advanced and metastatic NSCLC in a real-world setting.

Conditions

• NSCLC

Interventions

Type	Name	Description
DRUG	Sugemalimab and Chemotherapy	Sugemalimab 1200mg plus 4-6 cycles of platinum-based chemotherapy as first-line therapy, followed by Sugemalimab 1200mg to 35 cycles, or until disease progression, or ICF withdrawn by participants, or death or unacceptable toxicity.

Timeline

• Start date: 2023-10-10
• Primary completion: 2027-05-01
• Completion: 2027-05-01
• First posted: 2025-11-25
• Last updated: 2025-11-25

Locations

1 site across 1 country: China